We would love to hear your thoughts about our site and services, please take our survey here.
Very long term holder, for what it's worth here is my view.
The market cap is low, driven down because of the poor performance of the previous management who failed to capitalise quickly enough on the pandemic which meant a product that was too late to market.
However, the products that were not pandemic related were continued and represent a big opportunity of the business. They are not valued into the current market cap.
Last week we saw a quick rise to 10p and I suspect the current SP will recover to that position. I think a market cap of £30m based on the current test in market is justified and probably much higher once it becomes a more global test. Stroke testing will increase this further. Possibly to £100m and will be the making of the business in 2025 and onwards.
Nothing since last weeks recovery to 10p has changed. So 10p+ is the short term likelihood. That already prices in the equity raise since this was known about when it climbed...
https://www.pulsetoday.co.uk/news/clinical-areas/cardiovascular/gp-practices-to-trial-genetic-testing-ahead-of-statin-ppi-and-antidepressant-prescribing/
I’m sure this has been spotted but this is the same group that was involved with the hearing loss pharmacogenetic test on genedrive…
Still here too CTW, gave up posting, no body is interested in a proper discussion either way. Should have sold higher and bought lower. We all felt is was undervalued otherwise that's what we would have done. Now we wait for the revenue lines to appear. Short term target £50m market cap based on AIHL sales and COVID POC....
There are two aspects to the Indian market in terms of testing, the public market (where the government are placing pricing requirements) and the private market such as DIVOC where there is room to charge more for a better test. I think GDR are smart in placing their product in the private markets first. Scale can bring the pricing down for public use, but it's a different ball game.
Sales in India now a certainty, look at DIVOCs testing numbers already, this can now be ramped up significantly....
My understanding is that all the POC molecular platforms are delayed due to added requirements being put on them... I'm happy to buy the dip that's coming our way, it won't be long as we are now Q2 so expect POC shortly!
The report was as expected, the only thing that wasn't expected is that the Company made a profit.
Lot's will get caught out in the coming weeks. The share price may well drop today based on the no significant covid sales, but this will change rapidly and those who buy the lows will do very well. I've held since 2016, this is the first time the business has made a profit, I continue to trade the rises and falls, this will soon create significant profits
another variant suspected of overcoming the current vaccines, only a matter of time... test, test, test
https://www.independent.co.uk/news/health/covid-uk-news-live-vaccine-test-cases-b1818275.html
Trevor Brown is just a smart person. He takes options rather than salary keeping investment to a minimum. His main trading happens when he has to keep a watch on what overall percentage he owns. I have investments here and in BRH and I've done incredibly well with both investments. I bought more here taking advantage of the dips. You can not blame TB for day traders creating peaks and troughs, just do your research, look at the market opportunity, and invest if you see potential. Don;t try and ride a bandwagon, if you see it you're already too late.
I've noticed over recent weeks the company has been getting better with almost weekly news flow, I think this will help the support levels along the way to the main sales event... £93m market cap could quickly become £200m when first US and India sales are announced... not long, actually could be next week since Beckman have now started their sales process
Just time now, Beckman completed an extensive evaluation of the GDR test on their platform, the result of which was a distribution agreement to sell the product to run on their platform. It is now just time to install customers and the US and EU represent the two largest markets for us... figures will soon come, I suspect an announcement on first sales shortly!
GDR have said this is worth upwards of £35m per year in the UK alone, assuming same 60% margin would give £100m MC just for the UK, potentially only 3% off the market. Certainly this should provide a re-rate